article thumbnail

Alkem signs agreement with US-based Sonnet BioTherapeutics to develop, commercialise its drug candidate for diabetic peripheral neuropathy in India

Express Pharma

Alkem Laboratories, has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings to develop, manufacture and commercialise the drug candidate SON-080 for the treatment of diabetic peripheral neuropathy in India. Diabetic peripheral neuropathy primarily affects the hands and lower limbs. “SON-080”

Diabetes 105
article thumbnail

STAT+: Pharmalittle: We’re reading about Sanders’ pharma pressure campaign, AstraZeneca’s new ADC factory, and more

STAT

After a few victories he’s claimed, he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight loss drugs. Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. AstraZeneca is investing $1.5

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties

STAT

The techs who were queried identified chemotherapies; ADHD medicines; three drugs for weight loss and diabetes — Mounjaro, Ozempic, and Wegovy — and local anesthetics such as lidocaine as the top drugs experiencing shortages.

article thumbnail

Diabetes Drug Shortages and Fake Ozempic

National Association of Boards of Pharmacy

Injectable diabetes medications including semaglutide, namely Wegovy and Ozempic, have been in shortage since 2022 , limiting patient access to the drug across the nation. Many other drugs have appeared on FDA’s shortage list in the past few years, including ADHD medications, chemotherapy treatments, and even antibiotics.

article thumbnail

Survey: 72% of Pharmacy Technicians’ Workflow Affected by Drug Shortages

Pharmacy Times

Chemotherapy, medication for attention deficit/hyperactivity disorder, glucagon-like peptide-1 agonists for weight loss and diabetes, and local anesthetics were among the drugs most affected by shortages.

article thumbnail

Panbela announces issuance of key patent in Japan

Express Pharma

months and an objective response rate (ORR) of 48%, both exceeding what is typical for the standard of care of gemcitabine + nab-paclitaxel suggesting potential complementary activity with the existing FDA-approved standard chemotherapy regimen. The post Panbela announces issuance of key patent in Japan appeared first on Express Pharma.

article thumbnail

EU Biosimilar Regulatory and Launch Updates

Big Molecule Watch

PAVBLU is further indicated for the treatment of visual impairment due to diabetic macular oedema (DME). If approved, Amgens PAVBLU and SKOJOY would be the fifth and sixth aflibercept biosimilars approved in the EU, following the approval of Biocons YESAFILI , Sandozs AFQLIR , Samsung Bioepiss OPUVIZ , and Formycons FYB203.